Alnylam Pharmaceuticals Inc (ALNY)vsModerna Inc (MRNA)
ALNY
Alnylam Pharmaceuticals Inc
$174.00
-25.13%
HEALTHCARE · Cap: $31.10B
MRNA
Moderna Inc
$222.76
+4.01%
HEALTHCARE · Cap: $85.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 116% more annual revenue ($4.80B vs $2.23B). ALNY leads profitability with a 16.1% profit margin vs -141.4%. ALNY earns a higher WallStSmart Score of 68/100 (B-).
ALNY
Strong Buy68
out of 100
Grade: B-
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.3%
Fair Value
$2546.59
Current Price
$174.00
$2372.59 discount
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$222.76
$88.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 60 in profit
Revenue surging 66.9% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Trading at 17.2x book value
0.0% earnings growth
Distress zone — elevated risk
Trading at 13.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Profitability is solid with margins at 16.1% and operating margin at 17.9%. Revenue growth of 66.9% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ALNY
The primary concerns for ALNY are P/E Ratio, Price/Book, EPS Growth.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ALNY profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.09 — expect wider price swings.
ALNY is growing revenue faster at 66.9% — sustainability is the question.
ALNY generates stronger free cash flow (41M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (68/100 vs 21/100), backed by strong 16.1% margins and 66.9% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?